The BIO International Convention Begins Day Three with Keynote Speech from Actor, Director and Advocate Rob Reiner
During today’s keynote, Jim Greenwood, President and CEO of BIO will interview actor, director and advocate Rob Reiner, who will share his poignant story of helping his son overcome his battle with drug addiction. During this week’s Convention, industry leaders and researchers are gathered to discuss strategies to stem the opioid crisis and progress in discovering next-generation non-addictive pain therapies.
Following the keynote, multiple sessions will focus on digital health, patient access and delivering value to patients. A special performance by Diana Ross at Ballroom Level will cap off day three of the Convention.
“As stewards of biotechnology, it’s our responsibility to ensure that our science is sound and delivers real value to patients who are counting on us,” said John Maraganore, chief executive officer, Alnylam Pharmaceuticals, BIO Board Chair and Co-chair of the 2018 BIO International Convention Steering Committee. “I’m looking forward to today’s important conversations and sharing more on Alnylam’s bold commitment to making a difference in patients’ lives.”
The exhibit hall will feature the BIO Patient Advocacy Pavilion with 62 separate patient advocacy organizations there to share perspectives and learn more about drug discovery and clinical development initiatives, enrollment optimization, clinical protocol and trial design.
Wednesday, June 6 Highlights Include:
- Fireside Chat: Deval Patrick, Managing Director, Double Impact, Bain Capital
Join us for a fireside chat with former Massachusetts Governor Deval Patrick.
11:00 a.m. – 12:00 p.m. l Room 205ABC, Level 2
- Start-Up Stadium: Empowering the Cutting-Edge Companies of Tomorrow, Today
Start-Up Stadium was designed to provide start-up companies with the opportunity to engage key members of the investment community, venture philanthropy groups, and BIO attendees. Stop by Start-Up Stadium between education sessions or meetings to watch these impressive companies pitch their products to a panel of investor judges.
11:00 a.m. – 1:00 p.m. | Level 1 North Lobby
2:00 p.m. – 4:00 p.m. | Level 1 North Lobby
- Fireside Chat: John Maraganore, PhD, Chief Executive Officer, Alnylam Pharmaceuticals
A fireside chat with John Maraganore, PhD, CEO at Alnylam Pharmaceuticals. Dr. Maraganore is leading Alnylam as they prepare to launch the first RNAi therapy. Prior to joining Alnylam, he held senior leadership roles at Millennium Pharmaceuticals, Biogen and ZymoGenetics.
2:00 p.m.– 3:00 p.m. l Room 254A, Level 2
- Fireside Chat: Mikael Dolsten, MD, PhD, President, Worldwide Research and Development, Pfizer, Inc.
A fireside chat with Mikael Dolsten, MD, PhD, President of Worldwide Research and Development at Pfizer. Dr. Dolsten is focused on advancing Pfizer’s scientific leadership in small molecule medicines, biotherapeutics and vaccines.
3:30 p.m. – 4:30 p.m. l Room 254A, Level 2
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.